VitalConnect secures $33M for stick-on vital sign tracker

The VitalPatch monitors eight vital signs, including heart rate and motion, and could detect changes in a patient's physiology earlier. (VitalConnect)

VitalConnect raised $33 million in series C funding, which will boost the commercialization of its disposable, adhesive biosensor for patient monitoring in hospitals or at home.

Launched in March last year, the VitalPatch is a small, wireless sensor that tracks eight vital signs: skin temperature, breathing rate, posture, motion, including falls, ECG, heart rate and variability in heart rate. The VitalConnect Platform integrates these data into a cloud-based system, where they are processed and analyzed, and may be viewed by healthcare professionals on a computer or mobile device.

The patch is powered by a disposable zinc battery, which can last up to four days.

Survey

Share your opinion. Take our five minute survey.

How do you select the most suitable advanced dosage forms for new molecules in your development pipelines? Share your insights in this 5-minute survey. The first 50 qualified respondents will receive a $5 Amazon gift card.

Continuous monitoring of vital signs could help spot changes in patient physiology sooner, which could improve care for patients and reduce time spent in intensive care.

RELATED: FierceMedicalDevices’ 2016 Fierce 15 - VitalConnect

“The integration of wearable biosensors into existing and emerging healthcare environments will change the care paradigm within hospitals as well as enable virtual care opportunities that were never before possible,” said VitalConnect CEO Nersi Nazari in a statement. “Biosensors, when paired with sophisticated data analytics platforms, have the unique opportunity to enable better care for patients while reducing costs for hospitals—a win for both patients and providers.”

MVM Life Science Partners and Baxter’s venture arm led the financing. Last June, VitalConnect picked up $17.5 million in debt from Perceptive Advisors and raised $7.8 million to bring its series B total to $22.1 million.

Suggested Articles

The Pfizer Foundation has awarded 20 grants to organizations involved in tackling infectious diseases in low- and middle-income countries.

The engineered stain of E. coli performed no better than placebo, leading Synlogic to conclude its money is better spent on other assets.

The FDA rejected the New Drug Application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.